Maternal puerperal sepsis · women at risk of preterm birth
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Maternal adverse effects of therapy · women at risk of preterm birth
Dexamethasone showed no clear difference in maternal adverse effects of therapy compared with betamethasone – maternal outcomes (moderate certainty).
1 finding from 1 review
Any known death after randomisation (fetal, neonatal, child, child as adult) · women at risk of preterm birth
Dexamethasone showed no clear difference in any known death after randomisation (fetal, neonatal, child, child… compared with betamethasone – fetal/neonatal outcomes (moderate certainty).
1 finding from 1 review
Respiratory distress syndrome · women at risk of preterm birth
Dexamethasone showed no clear difference in respiratory distress syndrome compared with betamethasone – fetal/neonatal outcomes (high certainty).
1 finding from 1 review
Intraventricular haemorrhage · women at risk of preterm birth
Dexamethasone showed no clear difference in intraventricular haemorrhage compared with betamethasone – fetal/neonatal outcomes (low certainty).
1 finding from 1 review
Chronic lung disease · women at risk of preterm birth
Dexamethasone showed no clear difference in chronic lung disease compared with betamethasone – fetal/neonatal outcomes (moderate certainty).
1 finding from 1 review
Necrotising enterocolitis · women at risk of preterm birth
Dexamethasone showed no clear difference in necrotising enterocolitis compared with betamethasone – fetal/neonatal outcomes (low certainty).
1 finding from 1 review
Nausea · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
1 finding from 1 review
Number of vomiting episodes · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient satisfaction · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any known death after randomisation (fetal, neonatal, child, child as adult) · women at risk of preterm birth
It is very uncertain whether dexamethasone: oral changes any known death after randomisation (fetal, neonatal, child, child… compared with intramuscular – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
Respiratory distress syndrome · women at risk of preterm birth
It is very uncertain whether dexamethasone: oral changes respiratory distress syndrome compared with intramuscular – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
Intraventricular haemorrhage · women at risk of preterm birth
It is very uncertain whether dexamethasone: oral changes intraventricular haemorrhage compared with intramuscular – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
Necrotising enterocolitis · women at risk of preterm birth
It is very uncertain whether dexamethasone: oral changes necrotising enterocolitis compared with intramuscular – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
Chronic lung disease · women at risk of preterm birth
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality up to 30 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in all‐cause mortality up to 30 days compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).
1 finding from 1 review
All‐cause mortality up to 120 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
It is very uncertain whether summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) changes all‐cause mortality up to 120 days compared with low‐dose dexamethasone (6 mg to 8 mg) (very low certainty).
1 finding from 1 review
Clinical improvement: discharged alive ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in clinical improvement: discharged alive ( compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).
1 finding from 1 review